|
Feb 23
|
Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025
|
|
Feb 12
|
Royalty Pharma Announces R&D Funding Collaboration With Biogen
|
|
Feb 12
|
Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...
|
|
Feb 11
|
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
|
|
Feb 11
|
Royalty Pharma Reports Q4 and Full Year 2024 Results
|
|
Feb 10
|
Royalty Pharma Earnings: What To Look For From RPRX
|
|
Oct 9
|
Royalty Pharma PLC (RPRX) Q2 2024 Earnings Call Highlights: Surpassing Growth Expectations and ...
|
|
Oct 9
|
Royalty Pharma plc (RPRX): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
|
Jul 24
|
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
|
|
Jun 22
|
Royalty Pharma plc (NASDAQ:RPRX) is largely controlled by institutional shareholders who own 70% of the company
|
|
May 28
|
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
|
|
May 22
|
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
|
|
May 22
|
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
|
|
May 13
|
Royalty Pharma to Present at Upcoming Investor Conferences
|
|
May 12
|
Here's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter Results
|
|
May 11
|
Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
|
|
May 10
|
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
|
|
May 9
|
Royalty Pharma Reports First Quarter 2024 Results
|
|
May 9
|
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
|
|
May 4
|
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21
|